Navigation Links
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Date:1/18/2008

the use of INTELENCE.

-- The use of other active antiretroviral agents with INTELENCE is

associated with an increased likelihood of treatment response.

-- In patients who have experienced virologic failure on a

NNRTI-containing regimen, do not use INTELENCE in combination with

only N[t]RTIs.

-- The risks and benefits of INTELENCE have not been established in

pediatric patients or in treatment-nave adult patients.

FDA accelerated approval procedures allow for earlier approval of drugs that provide a meaningful therapeutic benefit over existing treatment for serious or life-threatening diseases. The INTELENCE approval is based on the 24-week analysis of HIV viral load and CD4+ cell counts from the pooled analysis of the DUET-1 and -2 studies. Longer-term data will be required before the FDA can consider traditional approval for INTELENCE.

"It is very inspiring to our R&D organization to see an additional compound so quickly emerge from our pipeline and reach patients who need it," said Roger Pomerantz, M.D., FACP, President, Tibotec Research and Development. "With one of the most robust virology research and development programs in the industry, we are dedicated to continuing to deliver innovative approaches in HIV management in the years to come."

"The addition of INTELENCE following the launch of our first antiretroviral just two years ago is a significant milestone for Tibotec Therapeutics," said Glenn Mattes, President, Tibotec Therapeutics. "In partnership with Tibotec R&D, we are committed to continuing to bring new options to people living with HIV."

The NNRTI Class

INTELENCE is the first new NNRTI to be introduced in nearly 10 years. It is also the first NNRTI to show antiviral activity in patients with NNRTI-resistant virus. NNRTIs block reverse transcriptase, a key enzyme the HIV virus uses to replicate. NNRTI drug resistance occurs when HIV develops mutations that par
'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
2. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
3. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
4. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
5. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
6. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
7. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
10. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
11. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... 3, 2015  Guardant Health®, the leader in ... the performance and clinical utility of Guardant360® on ... and poster presentations at the International Association for ... on Lung Cancer. These abstracts were submitted by ... Davis; the University of Chicago; Sarah Cannon Research ...
(Date:9/3/2015)... PUNE, India , September 3, 2015 ... "Chromatography Instruments Market by System (LC (HPLC, UHPLC, Flash), ... (Reverse Phase Columns, Syringe Filters, Vials) - Analysis & ... Instruments Market is expected to reach around 9.223 Billion ... a CAGR of 5.5%. Browse 141 tables ...
(Date:9/2/2015)... 2, 2015 Axovant Sciences Ltd. (NYSE:  AXON), a ... today announced upcoming presentations at three investor conferences: ... 2015 Healthcare Conference in New York ... 10 at 2:00 PM at the BioCentury NewsMakers Conference in ... Hotel & Conference Center , Thursday, September 17 at ...
(Date:9/2/2015)... 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "Biochips ... to their offering. This report is ... and applications. The report starts with a description ... markets. Technologies include array comparative genomic hybridization (CGH), ...
Breaking Biology Technology:Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 2Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 3Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 4Chromatography Instruments Market Worth $ 9.223 Billion by 2020 2Chromatography Instruments Market Worth $ 9.223 Billion by 2020 3Chromatography Instruments Market Worth $ 9.223 Billion by 2020 4Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2
... ANDS ) announced today that it will present at ... 3, 2008 at 9:30 a.m. EST (6:30 a.m. PST) at the ... Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will ... ANA598 and ANA773 in hepatitis C and ANA773 in cancer. , ...
... Nov. 25 Sangamo BioSciences,Inc. (Nasdaq: SGMO ... will provide an update on the progress of Sangamo,s ... business strategy at,4:30 pm (ET) on Tuesday, December 2, ... in New York. The company will also update ...
... that Scott Jackson, chief executive officer, is scheduled to present ... New York and the 2008 Mid-Atlantic Capital Conference in Philadelphia. ... update on the company,s clinical development programs. The presentations ... Piper Jaffray Health Care ...
Cached Biology Technology:Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference 2Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference 2Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference 2
(Date:8/20/2015)... The wearable technology market has traditionally ... healthy. However, wearable technology has the potential to ... improve diagnostic capabilities and therapeutic outcomes. Today, Leaf ... Technologies Conference 2015 , where Barrett Larson ... healthcare.    "Over the past decade, ...
(Date:8/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... Alliance and the EMV Migration Forum.  ... Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. direct ... promoting adoption of smart card technology. To ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas ... key contributor to the Submission Content Management ... IRISS, a non-profit forum. Dedicated to the Implementation ... a neutral platform for industry, vendors, health ... information and work towards a standard method ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... 3, 2008 -- Rice University nanophotonics pioneer Naomi Halas ... Research Excellence Award from the University of Pennsylvania,s Nano/Bio ... her numerous contributions in the innovative synthesis of nanostructures. ... address at NBIC,s NanoDay@Penn ceremonies Oct. 29 in Philadelphia. ...
... Erec Stebbins, associate professor at The Rockefeller University, has ... Institutes of Health for a project aimed at exploiting ... into specific cells for therapeutic purposes. The award, which ... by the NIH September 3. The EUREKA program ...
... the American Museum of Natural History have received a ... explore plant evolution and to create a public database ... of proteins found in two plant genomes. The three-year ... investigate ground-breaking methods for exploring the evolution, structure, and ...
Cached Biology News:C. Erec Stebbins awarded prestigious EUREKA grant 2NYU, American Museum of Natural History receive $1.6 million NSF grant 2
The Programmable MP-5000P-F Power Supply can be applied for any Microfluidic application....
Rab GDP dissociation inhibitor beta...
... POWER 500V Programmable Power Supply are ... can handle virtually any application from ... blotting. It is unique in offering ... MAX POWER Programmable Power Supply is ...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
Biology Products: